Biomarker Accelerator Program
CurePSP's Biomarker Accelerator Program funds research to discover and validate biomarkers for better diagnosis and tracking of PSP and CBD.
Funder: CurePSP
Due Dates (Anticipated): December 2026 (Letters of Intent)
Funding Amounts: Up to $100,000 total for 1–2 years per project; direct costs only, no indirects
Summary: Supports innovative biomarker research advancing diagnosis, prognosis, and disease progression for PSP and CBD.
Key Information: All dates are projected; confirm on program page before applying.
Description
The Biomarker Accelerator Program from CurePSP is designed to catalyze biomarker discovery and validation projects relevant to progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). The program seeks to fund research that advances diagnostic, prognostic, and disease progression markers, as well as novel biomarker platforms and modalities. By supporting both pre-clinical and clinical-level studies, CurePSP aims to accelerate the development of effective clinical interventions for these neurodegenerative tauopathies. Projects should align with CurePSP’s mission and focus on biomarker validation, early diagnostic markers, and the development or validation of diagnostic platforms to improve the understanding, diagnosis, and treatment of PSP and CBD.
